Medtronic Intersect ENT Propel Contour
In Stock: 45 Eaches
Express: Need it tomorrow? Order in next 2 hours 8 minutes and choose overnight shipping at checkout.
The item listed above is expired and may be used for educational, training, and non-clinical research purposes only. Any product information appearing below, including the product indication statement, pertains to an in-date item only.
Description
Medtronic Intersect ENT Propel (Mometasone Furoate) Contour Sinus Implant
The PROPEL™ sinus implant maintains patency and locally delivers steroid to the sinus mucosa in patients 18 years and older following sinus surgery.
Product Code: 50011
- One Sinus Implant
- One Delivery System
- For sinus ostia, frontal, and maxillary
PROPEL™ is the first and only methoxy propyl acetate (PMA)-approved steroid eluting sinus implant. The PROPEL™ family of implants offers three steroid-eluting implants, allowing ear, nose, and throat (ENT) physicians to select the best option that confirms to the anatomical needs of their patients
- PROPEL™ mometasone furoate implant for ethmoid sinus
- PROPEL™ mini mometasone furoate implant for ethmoid sinus and frontal sinus opening
- PROPEL™ contour mometasone furoate implant for sinus ostia, frontal, and maxillary
Sterilization
- Device Packaged as Sterile: Yes
- Requires Sterilization Prior to Use: No
- Single-Use
- Disposable
Additional Details
- Company Name: Medtronic Xomed, Inc.
- FDA Product Code: OWO
- FDA Product Code Name: Drug-eluting sinus stent
- GMDN Term Code: 61370
- GMDN Term Name: Drug-eluting paranasal sinus stent
- GMDN Term Definition: A bioabsorbable device with a drug coating intended to be implanted into a paranasal sinus (e.g., frontal, sphenoidal, ethmoidal, maxillary) to maintain sinus patency in the treatment of chronic sinusitis. The drug coating is intended to reduce inflammation and polyps to facilitate the separation of sinus mucosal tissues. The device is made of synthetic polymer(s) capable of being degraded and absorbed by body tissues, and is designed to allow for the slow release of the drug coating. It is endoscopically implanted via the nasal passageway; disposable devices associated with implantation may be included.
Additional information
| Size | 1 |
|---|---|
| Arms | N/A |
| Manufacturer | |
| Type | Propel |
| Unit | box of 1 |
- FDA Product Code: OWO
- FDA Product Code Name: Drug-eluting sinus stent
- GMDN Term Code: 61370
- GMDN Term Name: Drug-eluting paranasal sinus stent
- GMDN Term Description: A bioabsorbable device with a drug coating intended to be implanted into a paranasal sinus (e.g., frontal, sphenoidal, ethmoidal, maxillary) to maintain sinus patency in the treatment of chronic sinusitis. The drug coating is intended to reduce inflammation and polyps to facilitate the separation of sinus mucosal tissues. The device is made of synthetic polymer(s) capable of being degraded and absorbed by body tissues, and is designed to allow for the slow release of the drug coating. It is endoscopically implanted via the nasal passageway; disposable devices associated with implantation may be included.
Intersect ENT
Intersect ENT, now part of Medtronic, specializes in drug-delivery sinus implants designed to treat chronic rhinosinusitis and improve postoperative outcomes following sinus surgery. Its core products—PROPEL, PROPEL Mini, and PROPEL Contour—are bioresorbable steroid-eluting implants that deliver anti-inflammatory medication directly to the sinus tissue while propping open the sinus cavities during healing. Intersect ENT also developed the SINUVA implant, an in-office option for recurrent nasal polyps. By combining localized drug delivery with mechanical support, Intersect ENT offers ENT specialists innovative, minimally invasive solutions to reduce inflammation, minimize the need for oral steroids, and improve long-term sinus health.
